Shots:

• The US FDA has put a partial clinical hold on Aprea’s clinical program that evaluates eprenetapopt + acalabrutinib or with venetoclax and rituximab in patients with lymphoid malignancies. The FDA’s decision is related to the safety & efficacy data from the P-III MDS study
• The patient enrollment will be pause until the clinical hold is resolved while the patients will continue to receive study treatment who obtains the clinical benefit
• The company plans to work closely with the FDA to address the questions & investigates to resolve the clinical hold shortly

  | Ref: Aprea Therapeutics | Image: Aprea Therapeutics